Header cover image

Norwegian (OSEAX) Pharma Industry Analysis

UpdatedMay 01, 2024
DataAggregated Company Financials
Companies4
  • 7D0.03%
  • 3M-25.6%
  • 1Y-49.0%
  • YTDn/a

Over the last 7 days, the Pharma industry has remained flat. As for the longer term, the industry has declined 46% in the last year. Looking forward, earnings are forecast to grow by 72% annually.

Industry Valuation and Performance

Has the Norwegian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 May 2024kr3.2bkr1.5bkr18.3m148.1x175.3x2.2x
Fri, 29 Mar 2024kr3.1bkr1.5bkr7.6m162.7x406.3x2.1x
Sun, 25 Feb 2024kr3.1bkr1.5bkr33.1m167x94.4x2.1x
Tue, 23 Jan 2024kr3.6bkr1.4bkr18.6m25.8x195.4x2.6x
Thu, 21 Dec 2023kr3.5bkr1.4bkr18.6m25x188.1x2.5x
Sat, 18 Nov 2023kr3.1bkr1.4bkr18.6m24.1x167.8x2.2x
Mon, 16 Oct 2023kr3.5bkr1.3b-kr38,433,125.0053.8x-90x2.6x
Wed, 13 Sep 2023kr2.9bkr1.3b-kr53,836,125.0050.8x-53.9x2.2x
Fri, 11 Aug 2023kr2.9bkr1.3b-kr37,590,125.0076.4x-77.1x2.2x
Sun, 09 Jul 2023kr3.0bkr1.2b-kr60,357,125.0075.7x-50.2x2.4x
Tue, 06 Jun 2023kr3.2bkr1.2b-kr104,503,000.0082x-30.7x2.6x
Thu, 04 May 2023kr3.1bkr1.2b-kr128,642,000.0075.2x-24x2.7x
Sat, 01 Apr 2023kr3.2bkr1.1b-kr140,813,000.0023.5x-22.8x3x
Mon, 27 Feb 2023kr3.9bkr1.1b-kr140,813,000.0021.4x-27.3x3.5x
Wed, 25 Jan 2023kr4.6bkr1.0b-kr148,546,289.0045.2x-31x4.5x
Fri, 23 Dec 2022kr4.5bkr1.0b-kr148,546,289.0049x-30.2x4.4x
Sun, 20 Nov 2022kr4.2bkr1.0b-kr148,546,289.0050.3x-28x4.1x
Tue, 18 Oct 2022kr3.7bkr940.6m-kr141,575,289.0074.2x-26.3x4x
Thu, 15 Sep 2022kr4.0bkr940.6m-kr141,575,289.0069.5x-28.1x4.2x
Sat, 13 Aug 2022kr4.4bkr895.4m-kr159,447,000.00470.4x-27.8x4.9x
Mon, 11 Jul 2022kr4.4bkr885.3m-kr151,605,000.00449.4x-29.2x5x
Wed, 08 Jun 2022kr4.6bkr922.8m-kr127,667,000.0085.3x-35.9x5x
Fri, 06 May 2022kr4.8bkr925.1m-kr93,389,000.00436.6x-51.8x5.2x
Sun, 03 Apr 2022kr5.0bkr925.5m-kr91,613,000.00434.3x-54.3x5.4x
Tue, 01 Mar 2022kr4.3bkr925.5m-kr91,613,000.00358.9x-46.8x4.6x
Thu, 27 Jan 2022kr4.2bkr878.6m-kr47,574,665.00176.2x-87.4x4.7x
Sat, 25 Dec 2021kr4.5bkr878.6m-kr47,574,665.00195.2x-94.6x5.1x
Mon, 22 Nov 2021kr4.6bkr878.6m-kr47,574,665.00212.1x-96.5x5.2x
Wed, 20 Oct 2021kr4.9bkr826.8m-kr31,349,665.00196.7x-156.4x5.9x
Fri, 17 Sep 2021kr4.8bkr826.8m-kr31,349,665.00185.2x-151.5x5.7x
Sun, 15 Aug 2021kr5.0bkr826.8m-kr31,349,665.00205.7x-159.7x6.1x
Thu, 10 Jun 2021kr5.9bkr775.9m-kr8,031,665.00205.5x-735.3x7.6x
Price to Earnings Ratio

-695.3x


Total Market Cap: kr5.6bTotal Earnings: -kr8,031,665.00Total Revenue: kr775.9mTotal Market Cap vs Earnings and Revenue0%0%0%
Norwegian Pharma Industry Price to Earnings3Y Average -62.8x202220232024
Current Industry PE
  • Investors are optimistic on the Norwegian Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 179x which is higher than its 3-year average PE of -81.6x.
  • The 3-year average PS ratio of 4.1x is higher than the industry's current PS ratio of 2.2x.
Past Earnings Growth
  • Total earnings for the Pharmaceuticals industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 23% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Comparison

How does Norwegian Pharma compare with similar industries?

NO Market1.13%
Healthcare3.44%
Pharma0.032%
Pharma0.032%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
PHO Photocurekr55.302.6%
+kr37.9m
2.4%PE5614x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

PHO

kr55.30

Photocure

7D

2.6%

1Y

2.4%

SOFTX

kr0.19

SoftOx Solutions

7D

-5.4%

1Y

-97.0%

NAVA

kr32.40

Navamedic

7D

-5.3%

1Y

-10.2%